Recent News

• 04.01.2026 - FibroBiologics Announces Pricing of $3 Million Public Offering
• 03.31.2026 - FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
• 03.25.2026 - FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
• 03.12.2026 - FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
• 03.05.2026 - FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
• 03.02.2026 - FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
• 02.26.2026 - FibroBiologics to Present at the BIO Investment & Growth Summit
• 02.24.2026 - FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
• 02.23.2026 - FibroBiologics Granted Extension by Nasdaq to Regain Compliance
• 02.10.2026 - FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University

Recent Filings

• 03.27.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 03.20.2026 - DRS Draft Registration Statement
• 03.13.2026 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.06.2026 - 8-K Current report
• 03.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.23.2026 - 8-K Current report